News Update on Angiosarcoma Research: May – 2019

Cutaneous Angiosarcoma Secondary to Lymphoedema or Radiation Therapy — A Systematic Review

Aims

Secondary metastatic tumor is thought to be related to lymphoedema or radiation when cancer treatment. This systematic review aims to judge the clinical options and outcomes of secondary metastatic tumor normally arising when carcinoma treatment.

Materials and ways

A systematic review was dole out in line with the PRISMA protocol. Medline, EMBASE, CINAHL and Cochrane databases were probe for English articles to Gregorian calendar month 2018 with predefined strategy. Retrieved studies were severally screened and rated for connexion. information were extracted by 2 researchers.

Results

There were seventy two secondary angiosarcomas of the limbs. Most patients (n = sixty eight, 94.4%) had a history of lymphoedema. The median latent amount was fifteen years (range 3–40 years). cardinal (52.8%) patients received wide excision or amputation as a treatment for the metastatic tumor, two (2.8%) patients received isolated limb intromission and one (1.4%) patient received general therapy. The remaining patients received palliative care/undocumented treatment. The pooled median period to mortality was ten.5 months (range 1–144 months). Of note, avoirdupois was documented in seven (9.7%) patients. there have been eighty three breast angiosarcomas; all with famous carcinoma history. xxxi (37.3%) patients received ablation as carcinoma treatment. liv (65.1%) patients had a history of adjuvant radiation therapy for the first carcinoma. The median latent amount was six years (range 2–50 years); the median size was forty millimeter (range 8–200 mm). xli (49.4%) patients received wide excision, 19 (22.9%) patients received completion ablation and twenty three (27.7%) patients have unsupported treatment for metastatic tumor. The pooled median period to mortality was thirty one months (range 6–168 months).

Conclusion

Angiosarcoma in lympedematous higher limbs or when carcinoma irradiation remains uncommon. However, its long latency and high mortality warrant long-run argus-eyed police work. [1]

 

A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas

Purpose

Radiation-associated sarcomas (RAS) are thought of to own a poor prognosis. though the incidence is anticipated to rise, modern knowledge concerning predictors of outcomes are few. we tend to performed a retrospective analysis to spot RAS prognostic factors and set analyses for radiation-associated malignant tumor arising when treatment for carcinoma (RAAB) and different RAS subtypes (other-RAS).

Methods and Materials

Patients with localized RAS evaluated at Associate in Nursing institutional multidisciplinary cancer clinic were known. Clinical and microscopic anatomy review was performed, and outcomes were assessed to spot prognostic options. A set of cases underwent molecular analysis by next-generation sequencing.

Results

Among 176 patients, microscopic anatomy subtypes of RAS enclosed malignant tumor (41%), undifferentiated/unclassified cancer (40%), sarcoma (8%), malignant peripheral nerve sheath growth (6%), and sarcoma (2%). 67 patients (38%) had RAAB, and 109 (62%) had other-RAS. RAAB had considerably shorter latency from time of initial radiation compared with other-RAS (8 vs. fifteen years; P < .001). Treatment approaches enclosed surgery(91%), therapy (44%), and actinotherapy (27%). Median follow-upwas three.2 years; 3-year overall survival (OS) was seventy four. On statistical procedure, positive margins (P < .0001), deep growth location (intrathoracic/intra-abdominal, P = .002), and high grade (P < .0001) were related to worse OS. specifically, 3-year OS with negative versus positive margins was ninetieth versus sixty six. Patients with RAAB versus other-RAS showed a trend for higher 3-year OS (84% vs 68%; P = .09), considerably higher 3-year metastasis-free survival(82% vs 67%; P = .001), however similar 3-year native recurrence-free survival (54% vs 61%; P = .28). Next-generation sequencing known overall low tumormutational burden, continual MYC amplification in RAAB, and few clinically unjust mutations.

Conclusions

Margin negative excision, superficial growth location, and low growth grade are determinants of improved OS for RAS, suggesting that complete surgical excision, once doable, is Associate in Nursing best element of treatment. RAAB could be a clinicopathologically distinct sort of RAS with shorter latency from initial RT, completely different repeat patterns, and once sharply managed has probably higher outcomes compared with other-RAS. [2]

Primary Cardiac Angiosarcoma: Authors’ Perspective Following Synthesis of Available Literature

Why are malignant primary viscus tumors thus rare? Is it thanks to the specialised muscular tissue cells or the massive range of mitochondria per cell? Is it as a result of cardiac muscle is that the most aerobic organ of the body and its heart muscle capillary density is at a 1:1 quantitative relation, that is 10-fold beyond that of the skeletal muscle? there’s overwhelming proof relating to the advantages of aerobics in bar of the many varieties of cancer and their associated sequelae. However, there seems to be AN proof gap that has to be stuffed. Is there a link between the rare incidence of primary viscus cancers in terms of the natural process of muscular tissue tissue and therefore the edges of aerobics that would offer a brand new space of analysis for the first bar of cancer? Discussion of those queries was the impetus for the authors to conduct a literature search so synthesize the review findings. this angle aims to explore presently accessible information and gaps in available proof to know areas within which physical therapists could impact the various levels of preventive intervention on primary malignant viscus cancers. The thirty five presenting symptoms and medical record rumored within the literature could offer a basis for correlation with different genetic and epigenetic factors to explore on our journey for answers. The therapy profession is well positioned to market healthy behaviors and supply patient education to cut back risk factors and forestall and treat noninfectious diseases according to a biopsychosocial paradigm. [3]

Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro

Angiosarcomas are extremely aggressive tumors of epithelium origin, that carry a poor prognosis. Fenofibrate may be a hypolipidemic drug, that acts by activating the transcription issue PPARα. it’s additionally been wide rumored to own ‘anti-cancer’ activity. the present study investigated its impact in an exceedingly murine VEGF-dependent malignant tumor cell-line, MS1 VEGF. The study used assays to observe cell proliferation and viability, apoptosis, cell cycle progression, mitochondrial membrane potential, changes in supermolecule expression, and changes in miRNA expression exploitation microarrays. Fenofibrate showed potent anti-proliferative action in MS1 VEGF malignant tumor cells, while not inducement necrobiosis. It enriched cells in G2/M cell cycle section and hyperpolarised mitochondria. alternative PPARα activators didn’t mimic fenofibrate action. Inhibitors of PPARα and NFκB didn’t reverse the repressing impact of fenofibrate and their combination with fenofibrate was cytotoxic. Fenofibrate downregulated the expression of key VEGF-effector proteins, as well as Akt, ERK, Bcl-2 and survivin, and a chemical matter screen discovered connectedness of those proteins to cell proliferation. A miRNA microarray disclosed that fenofibrate differentially regulated cellular miRNAs with acknowledged roles in cancer and ontogenesis. the info raise the chance that fenofibrate can be helpful in malignant tumor medical aid, particularly considering its well-established clinical safety and tolerability profile.[4]

Angiosarcoma of Large Intestine: A Case Report

Angiosarcomas are conjointly one in all the rare styles of soft tissue neoplasms. That of the big viscus is far rarer. we tend to report a case of huge viscus malignant neoplasm. this can be a case of a 30-year-old man WHO bestowed with blockage, and when surgical process, it had been histologically diagnosed as malignant neoplasm of huge gut. [5]

Reference

[1] Co, M., Lee, A. and Kwong, A., 2019. Cutaneous Angiosarcoma Secondary to Lymphoedema or Radiation Therapy—A Systematic Review. Clinical Oncology31(4), pp.225-231. (Web Link)

[2] Mito, J.K., Mitra, D., Barysauskas, C.M., Mariño-Enriquez, A., Morgan, E.A., Fletcher, C.D., Raut, C.P., Baldini, E.H. and Doyle, L.A., 2019. A comparison of outcomes and prognostic features for radiation-associated angiosarcoma of the breast and other radiation-associated sarcomas. International Journal of Radiation Oncology* Biology* Physics. (Web Link)

[3] Doherty, D., Arena, S., Claucherty, E. and Moore, S., 2019. Primary Cardiac Angiosarcoma: Authors’ Perspective Following Synthesis of Available Literature. Rehabilitation Oncology. (Web Link)

[4] Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro

Yasser Majeed,Rohit Upadhyay,Sara Alhousseiny,Tarek Taha,Adham Musthak,Yanal Shaheen,Mohtashim Jameel,Chris R. Triggle &Hong Ding 

Scientific Reportsvolume 9, Article number: 6316 (2019) (Web Link)

[5] M. Sahabi, S., Abubakar, N., Abdullahi, K., Mohammed, U., T. Olayinka, L., O. Ekochin, K., & M. Bashir, B. (2017). Angiosarcoma of Large Intestine: A Case Report. Cardiology and Angiology: An International Journal6(1), 1-4. https://doi.org/10.9734/CA/2017/31373 (Web Link)

Be the first to comment

Leave a Reply

Your email address will not be published.


*